Clinical Trial

A Clinical Study of HMPL-506 in Patients With Hematological Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, multicenter, open-label clinical study of HMPL-506 administered orally in the treatment of hematological malignancies. Only eligible patients who provide the signed informed consent form (ICF) can be enrolled in this study. The study consists of two phases, i.e., a dose escalation phase and a dose expansion phase. The study is expected to enroll approximately 60 to 132 patients, including approximately 30 to 38 patients in the dose escalation phase and approximately 30 to 72 patients in the dose expansion phase.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-04-24; most recent amendment 2025-09-26.
Status change: Not Yet Recruiting → Recruiting 2024-06-19
Trial Details
NCT Number NCT06387082
Lead Sponsor Hutchmed
Conditions Hematological Malignancies
Enrollment 132 participants
Start Date 2024-05-27
Primary Completion 2027-10-08 (estimated)
Study Completion 2027-12-08 (estimated)
Updated on ClinicalTrials.gov 2025-09-29